Evidence map›Paper›PMID 40777711›Full record

ArticleCureus2025

Unmasking Diabetes in a Young Adult Male: A Case Report.

Jimmy Joseph

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jimmy JosephInternal Medicine, Aster DM Healthcare, Dubai, ARE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Maturity-onset diabetes of the young (MODY) is an underdiagnosed form of monogenic diabetes characterized by early-onset, autosomal dominant inheritance, and non-insulin-dependent hyperglycemia. This report presents the case of a 31-year-old male diagnosed with diabetes mellitus four years ago, and initially treated with biphasic insulin due to hyperglycemic symptoms, including polyuria, polydipsia, and weight loss. He had no history of diabetic ketoacidosis. Persistent hyperglycemia despite insulin therapy prompted further evaluation. A strong family history of early-onset diabetes in his father and paternal aunt raised suspicion for MODY. Laboratory investigations showed absent autoantibodies (anti-GAD, anti-ICA) and low C-peptide levels. A trial of glimepiride, a sulfonylurea, led to marked glycemic improvement, allowing complete discontinuation of insulin within six months. This clinical response supported a presumptive diagnosis of MODY, likely the HNF1A or HNF4A subtype, although genetic confirmation is pending due to cost constraints. This report underscores the importance of considering MODY in young patients with atypical diabetes presentations, especially those with a strong family history and antibody-negative, insulin-independent diabetes. Early recognition can guide appropriate therapy, reduce treatment burden, and prompt family screening.

Indexed as

glycated hemoglobin (hba1c)insulinmodymonogenic diabetessulphonylurea

Identifiers

PMID40777711
PMCPMC12329610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.